Also listed on Tocagen, Inc., an earlier holder on the record. The recorded assignments below show how it moved.

Term ends Jun 30, 2029 · Medium confidence

Computed 20-year base term

Why Medium: The disclaimer's references carry disclaimers of their own not yet read (US 9,889,133), so the cap could be lower.

Held by Denovo Biopharma LLC

Filed Feb 7, 2018 as application 15/891,243 · Granted Oct 22, 2019

Base term, 20 years from filing

Today

20 years from filing

Term ends Jun 30, 2029

2009 2029

Clock starts
Jun 30, 2009

Term ends
Jun 30, 2029

Granted
Oct 22, 2019

base term fee events Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know

None

Term adjustment

No prosecution delay on this record.

No effect

Terminal disclaimer

Resolved from the filed document, referencing US 9,320,738, US 9,889,133, to Jun 30, 2029. The term already ends on or before that date, so the cap shortened nothing.

1 of 2

Maintenance fees paid

Two maintenance fees can end this term early, the ones due 3.5 and 7.5 years from grant; the third one's grace period runs past the term end. This counts the ones the record shows paid.

Family applications on record here

Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. 1 of 2 maintenance fees is paid so far. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.

Step	Input	Date after this step	Confidence
Base term, 20 years from filing	Clock starts Jun 30, 2009, when application PCT/US2009/049322, the earliest non-provisional in its chain, was filed (this one was filed Feb 7, 2018)	Jun 30, 2029	High confidence
Continuity chain	Every parent in the chain resolved	no change	High confidence
Patent term adjustment	None on file	no change	High confidence
Terminal disclaimer cap	Disclaimer resolved from the filed document (refs US 9,320,738, US 9,889,133)	resolves to Jun 30, 2029, no earlier than this term, so no change	Medium confidence
Patent term extension	None on file	no change	High confidence
Fee events	1 of 2 maintenance fees paid	In force	High confidence
Computed term end	The steps above, in order	Jun 30, 2029	Medium confidence

This family

Application PCT/US2009/049322	PCT application no patent term	no patent term
US 9,320,738	In force Mar 2030	Mar 2030
US 9,889,133	Lapsed on the fee record Feb 2026	Feb 2026
US 10,449,194	this patent Jun 2029	Jun 2029
US 11,191,764	Lapsed on the fee record Dec 2025	Dec 2025

The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.

Recorded	Assignor	Assignee	Conveyance
Apr 11, 2019 Reel 48865, frame 404	Gruber, Harry E.; Jolly, Douglas J.; Olmstead, Kay	Tocagen Inc.	Assignment of Assignor's Interest
Nov 4, 2019 Reel 50909, frame 548	Tocagen Inc.	Oxford Finance LLC, as Collateral Agent	Security Interest
Apr 23, 2020 Reel 52482, frame 439	Oxford Finance LLC	Tocagen, Inc.	Release of Security Interest
Jul 13, 2020 Reel 53192, frame 140	Tocagen Inc.	Denovo Biopharma LLC	Assignment of Assignor's Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

What's changing

Jun 2029

Term ends Jun 30, 2029. Maintenance fees still fall due before then

Terminal disclaimer

A terminal disclaimer resolved from the filed document, referencing US 9,320,738, US 9,889,133, ends no earlier than this term, so it caps nothing.

Citations

later US patents cite this one

That is below the median of utility patents granted in 2019 in our data, the only group it is compared against. How we rank

Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built

Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.

Formulations of 5-Fluorocytosine and Uses Thereof